William Everett Unloaded 2,500 Shares of Issuer Direct (NYSEAMERICAN:ISDR); Supernus Pharmaceuticals (SUPN) Shorts Raised By 16.91%

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had an increase of 16.91% in short interest. SUPN’s SI was 4.08 million shares in March as released by FINRA. Its up 16.91% from 3.49M shares previously. With 993,000 avg volume, 4 days are for Supernus Pharmaceuticals Inc (NASDAQ:SUPN)’s short sellers to cover SUPN’s short positions. The SI to Supernus Pharmaceuticals Inc’s float is 8.23%. The stock increased 2.44% or $1.05 during the last trading session, reaching $44.1. About 422,073 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since March 8, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

William Everett – а smart insider in Issuer Direct Corp who’s the current shareholder — sold some 2,500 shares of Issuer Direct Corp, with a market value roughly U.S Dollars 42,325 at an average price-per-share of U.S Dollars 16.9. At present, he has in hand 21,333 shares or about 0.70% of the company’s total market capitalization. The deal was disclosed in a report that was filed with the U.S. Security & Exchange Commission on March 08, 2018, which is available for online access here.

Investors sentiment increased to 1.1 in 2017 Q3. Its up 0.12, from 0.98 in 2017Q2. It improved, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Amer International Group holds 37,920 shares. Tci Wealth Advisors Inc invested in 0% or 97 shares. Fiera Cap has 0.2% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 1.04 million shares. State Board Of Administration Of Florida Retirement System accumulated 23,677 shares. Pub Sector Pension Inv Board, Quebec – Canada-based fund reported 31,716 shares. The United Kingdom-based Ahl Prtn Llp has invested 0.08% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Parkside Bank reported 31 shares. Principal Financial Group Inc stated it has 406,775 shares or 0.02% of all its holdings. Lenox Wealth Mgmt Inc accumulated 8,588 shares. Comerica Retail Bank invested in 0.02% or 53,718 shares. Thomson Horstmann And Bryant Inc reported 26,251 shares. Dekabank Deutsche Girozentrale reported 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). First Republic Invest Inc has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Citadel Advsrs Ltd Limited Liability Company holds 0% or 73,903 shares. Jane Street Group Ltd Liability reported 0% stake.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 38 analyst reports since August 26, 2015 according to SRatingsIntel. B. Riley & Co maintained the stock with “Buy” rating in Wednesday, November 8 report. The company was maintained on Thursday, November 5 by Northland Capital. Piper Jaffray maintained the stock with “Hold” rating in Friday, October 27 report. Stifel Nicolaus maintained the shares of SUPN in report on Monday, July 17 with “Buy” rating. On Thursday, August 3 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Outperform” rating by Northland Capital on Wednesday, October 28. The firm has “Hold” rating by Zacks given on Wednesday, August 26. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Buy” rating by Janney Capital on Monday, December 4. The firm has “Buy” rating by Stifel Nicolaus given on Friday, September 1. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Neutral” rating by PiperJaffray on Monday, July 17.

Since January 2, 2018, it had 0 buys, and 7 selling transactions for $8.26 million activity. Vaughn Victor sold $2.21M worth of stock. $899,500 worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was sold by Bhatt Padmanabh P. on Wednesday, January 17. PATRICK GREGORY S also sold $2.18 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, January 11.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $2.27 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 40.83 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Investors sentiment increased to 1.33 in 2017 Q3. Its up 0.33, from 1 in 2017Q2. It increased, as 0 investors sold Issuer Direct Corporation shares while 3 reduced holdings. 2 funds opened positions while 1 raised stakes. 136,884 shares or 46.20% less from 254,442 shares in 2017Q2 were reported. Vanguard Grp has 12,138 shares. Renaissance Tech Limited Liability Corp invested in 22,400 shares. Acadian Asset Mngmt Ltd Liability Corporation invested in 2,221 shares or 0% of the stock. Advisory Service Ntwk Ltd Liability Corporation accumulated 4 shares. Blackrock accumulated 0% or 6,883 shares. Geode Capital Mgmt Limited Company reported 35,897 shares or 0% of all its holdings. 25,000 are held by Bridgeway Mngmt. Morgan Stanley invested 0% in Issuer Direct Corporation (NYSEAMERICAN:ISDR). Comerica Bancorp accumulated 12,500 shares. Deutsche Commercial Bank Ag holds 0% or 18,141 shares in its portfolio.

The stock decreased 2.07% or $0.35 during the last trading session, reaching $16.5. About 22,398 shares traded or 526.87% up from the average. Issuer Direct Corporation (NYSEAMERICAN:ISDR) has risen 123.64% since March 8, 2017 and is uptrending. It has outperformed by 106.94% the S&P500.

Issuer Direct Corporation provides disclosure management solutions, shareholder communications tools, and cloud compliance technologies in North America and Europe. The company has market cap of $50.04 million. It offers services and products that enable companies' to produce and distribute their financial and business communications online and in print. It has a 30.11 P/E ratio. The firm provides Platform id, a cloud communications and compliance system for corporate issuers, mutual funds, and compliance professionals.